Bioasis Technologies Inc., of Vancouver, British Columbia, said the results of an in vivo study of the treatment of metastatic HER2+ breast cancer brain tumors in an animal model using BT2111, their trastuzumab-melanotransferrin (Transcend) conjugate, have been published in Pharmaceutical Research.